GSK's COPD drug Nucala approved for market launch by the European Union
Show original
Glonghui, February 6th｜GlaxoSmithKline announced today that the European Commission has approved its monoclonal antibody maintenance therapy drug Nucala for uncontrolled chronic obstructive pulmonary disease (COPD). GlaxoSmithKline stated that this approval is based on positive data from the MATINEE Phase III clinical trial. There are over 390 millions COPD patients worldwide, with approximately 40 millions in Europe.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Federal Reserve Beige Book: Most districts expect slight and moderate economic growth
华尔街见闻•2026/03/04 19:10
Trending news
MoreData: In the past 24 hours, the total liquidation across the network reached $574 millions, with long positions liquidated at $95.09 millions and short positions at $479 millions.
The European Union has streamlined the list of companies from France, Sweden, and the United Kingdom for the management of its established Scaleup Europe Fund program.
Crypto prices
More
Bitcoin
BTC
$73,603.27
+7.56%
Ethereum
ETH
$2,175.14
+9.64%
Tether USDt
USDT
$1
+0.03%
BNB
BNB
$662.92
+4.67%
XRP
XRP
$1.46
+6.97%
USDC
USDC
$1
+0.01%
Solana
SOL
$93.35
+9.68%
TRON
TRX
$0.2878
+2.49%
Dogecoin
DOGE
$0.1031
+15.38%
Cardano
ADA
$0.2824
+7.16%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now